Epitomee Medical Ltd (EPIT.TA)
ILA 1060.0
(2.42%)
ILA 1060.0
(2.42%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 10 Million | - | - | - | - |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | 10 Million | - | - | - | - |
| Operating Expenses | 16.76 Million | 11.06 Million | 8.77 Million | 3.84 Million | 3.27 Million |
| Selling, General and Administrative Expenses | 777 Thousand | 796 Thousand | 756 Thousand | 254 Thousand | 196 Thousand |
| Research and Development Expenses | 6.79 Million | 7.79 Million | 6.17 Million | 3.1 Million | 2.46 Million |
| Other Expenses | 9.18 Million | - | - | - | - |
| Cost and Expenses | 16.76 Million | 11.06 Million | 8.77 Million | 3.84 Million | 3.27 Million |
| Operating Income | -6.76 Million | -11.06 Million | -8.77 Million | -3.84 Million | -3.27 Million |
| Interest Expense | 57 Thousand | 11 Thousand | 2.71 Million | 66 Thousand | 82 Thousand |
| Income Tax Expense | - | -4.31 Million | -34 Thousand | 747 Thousand | -133 Thousand |
| Earnings before Tax | -5.68 Million | -15.39 Million | -11.51 Million | -3.16 Million | -3.48 Million |
| Net Income | -5.68 Million | -15.39 Million | -11.51 Million | -3.16 Million | -3.48 Million |
| Earnings Per Share Basic | -0.19 | -0.52 | -6.55 | -0.11 | -0.12 |
| Earnings Per Share Diluted | -0.19 | -0.52 | -6.55 | -0.11 | -0.12 |
| Weighted Average Shares Outstanding | 29.59 Million | 29.45 Million | 1.75 Million | 29.45 Million | 29.45 Million |
| Weighted Average Shares Outstanding (Diluted) | 29.59 Million | 29.45 Million | 1.75 Million | 29.45 Million | 29.45 Million |
| Gross Margin | 1.00 | - | - | - | - |
| EBIT Margin | -0.50 | - | - | - | - |
| Profit Margin | -0.57 | - | - | - | - |
| EBITDA | -4.98 Million | -15.02 Million | -8.57 Million | -2.87 Million | -3.21 Million |
| Earnings Before Tax Margin | -0.68 | - | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 1.8 Billion | 10 Million | 1.9 Billion | - |
| Cost of Revenue | 731.74 Thousand | - | 1.16 Million | - | - | 1.19 Million |
| Gross Profit | -731.74 Thousand | - | 1.8 Billion | 10 Million | 1.9 Billion | -1.19 Million |
| Operating Expenses | 995.22 Million | 972.47 Million | 15.84 Million | 9.58 Million | 2.31 Billion | 17.08 Million |
| Selling, General and Administrative Expenses | 366.6 Million | 358.22 Million | 4.33 Million | - | 276.93 Million | 3.6 Million |
| Research and Development Expenses | 534.61 Million | 522.39 Million | 11.51 Million | - | 580.56 Million | 13.48 Million |
| Other Expenses | 94 Million | 91.86 Million | - | - | - | - |
| Cost and Expenses | 995.22 Million | 972.47 Million | 17 Million | 9.58 Million | 2.31 Billion | 18.28 Million |
| Operating Income | -995.22 Million | -972.47 Million | -17 Million | -6.76 Million | 1.04 Billion | -18.28 Million |
| Interest Expense | 2.91 Million | - | - | 57 Thousand | - | 3.03 Million |
| Income Tax Expense | 5.00 | 91.86 Million | 2.00 | 8.31 Million | - | -3.00 |
| Earnings before Tax | -1.01 Billion | -989.81 Million | -2.53 Million | -5.68 Million | -127.59 Million | -18.01 Million |
| Net Income | -1.01 Billion | -989.81 Million | -2.53 Million | -5.68 Million | -127.59 Million | -18.01 Million |
| Earnings Per Share Basic | -34.04 | -33.26 | -0.08 | - | -4.29 | -0.61 |
| Earnings Per Share Diluted | -34.04 | -33.26 | -0.08 | - | -4.29 | -0.61 |
| Weighted Average Shares Outstanding | 29.75 Million | 29.75 Million | 29.75 Million | 29.59 Million | 29.73 Million | 29.59 Million |
| Weighted Average Shares Outstanding (Diluted) | 29.75 Million | 29.75 Million | 29.75 Million | 29.59 Million | 29.72 Million | 29.59 Million |
| Gross Margin | - | - | 1.00 | 1.00 | 1.00 | - |
| EBIT Margin | - | - | -0.01 | - | 0.57 | - |
| Profit Margin | - | - | -0.00 | -0.57 | -0.07 | - |
| EBITDA | -863.83 Million | -844.08 Million | -15.84 Million | - | 1.08 Billion | -17.08 Million |
| Earnings Before Tax Margin | - | - | -0.01 | -0.68 | 0.55 | - |
SCRSF
300243
GEECF
3678
4290
DMED